47 studies found for:    " September 07, 2011":" October 07, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Not yet recruiting A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
Conditions: Human Immunodeficiency Virus (HIV);   HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Maraviroc
2 Terminated
Has Results
A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
Conditions: Human Immunodeficiency Virus (HIV);   HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Raltegravir
3 Active, not recruiting Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Cobicistat;   Drug: Darunavir;   Drug: NRTI
4 Unknown  Efficiency of the Hepatitis B Sci-B-Vac Vaccine in HIV Positive Patients
Condition: HIV
Intervention: Biological: Sci-B-Vac
5 Completed Improving Uptake of Early Infant Diagnosis of HIV for the Prevention of Mother-to-child Transmission of HIV
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome
Intervention: Other: Text message
6 Unknown  Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)
Conditions: HIV Infection;   Hepatitis C
Intervention: Behavioral: Contigent voucher incentive (CVI)
7 Unknown  Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
Condition: HIV Infection
Intervention: Drug: Polyphenon E
8 Terminated A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
Condition: HIV Infection
Interventions: Biological: HIV-1 Tat/delta-V2 Env combined vaccine;   Biological: HIV-1 delta-V2 Env vaccine;   Biological: HIV-1 Tat vaccine 7.5 microg;   Biological: HIV-1 Tat vaccine 30 microg
9 Unknown  Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure
Condition: Human Immunodeficiency Virus (HIV)
Intervention: Behavioral: Enhanced Treatment Support (ETS)
10 Active, not recruiting Vitamin D Supplementation in HIV
Condition: HIV-infection/Aids
Interventions: Dietary Supplement: Vitamin D3;   Dietary Supplement: Placebo
11 Recruiting Implementation of Nucleic Acid Amplification Testing Screening to Identify Acute and Early HIV Infection
Condition: Acute HIV Infection
Intervention: Other: Nucleic Acid Amplification Testing
12 Completed The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort -
Condition: HIV-1-Associated Cognitive Motor Complex
Intervention:
13 Recruiting Maternal-fetal CD4 Microchimerism in HiV Exposed Newborns After Spontaneous Delivery and Cesarean Section
Condition: Human Immunodeficiency Virus
Intervention:
14 Unknown  Dimiracetam in Painful Neuropathies Affecting AIDS Patients
Condition: Acquired Immunodeficiency Syndrome
Interventions: Drug: Dimiracetam;   Drug: Dimiracetam 25 mg
15 Recruiting Reducing Cardiovascular Disease (CVD) Risk in HIV on Antiretroviral Therapy Over 12 Months
Conditions: HIV-1 Infection;   Cardiovascular Disease
Interventions: Other: Control;   Other: Intervention Group
16 Unknown  The Effect of Probiotics in HIV-1 Infection
Condition: HIV-1 Infection
Interventions: Dietary Supplement: Multi-strain probiotic;   Dietary Supplement: Placebo;   Other: Control
17 Recruiting Renal Transplantation and Raltegravir in HIV-Infected Patients
Conditions: HIV-1 Infection;   Chronic Renal Insufficiency
Intervention: Drug: Raltegravir
18 Completed Etravirine Plus 2 Analogs in HIV-infected Patients
Condition: HIV-1-infection
Intervention:
19 Active, not recruiting
Has Results
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg OAD;   Drug: darunavir 800mg OAD;   Drug: ritonavir 100mg OAD
20 Unknown  Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Conditions: Human Immunodeficiency Virus Infection;   Hepatitis C
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years